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In 2000 the U.S. Environmental Protection
Agency (U.S. EPA) released a draft risk assess-
ment for 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD) and other dioxin-like compounds
that evaluated the current state of knowledge
regarding exposures and health effects of
these compounds (U.S. EPA 2000). Included
in this assessment was an estimate derived
from epidemiological data of the 1% effective
dose, ED01, defined as the lifetime average
body burden of TCDD that would increase
the lifetime risk of cancer (all kinds) mortality
by 1%. Exposures to other dioxin-like com-
pounds were accounted for by using toxicity
equivalence factors (TEQ) to express the
amount of all dioxin-like compounds in a
mixture in TEQ units, deﬁned as the amount
of TCDD that would produce the same toxi-
city. The U.S. EPA risk assessment was criti-
cized by Starr (2001), who showed that the
epidemiologic data used by the U.S. EPA was
consistent with an elevated background can-
cer risk of about 32% relative to comparison
populations and no dioxin effect.
The U.S. EPA ED01 estimate was based on
data from three occupational cohorts: 5,172
workers from 12 U.S. chemical plants studied
by the National Institute for Occupational
Safety and Health—the “NIOSH cohort”
(Aylward et al. 1996; Fingerhut et al. 1991),
1,189 workers at a chemical plant in Hamburg,
Germany—the “Hamburg cohort” (Flesch-
Janys et al. 1998), and 243 workers exposed as
a result of an uncontrolled release in 1953 of
TCDD from an autoclave being used for
trichlorophenol production at a BASF AG
plant in Ludwigshafen, Germany—the “BASF
cohort” (Ott and Zober 1996). The NIOSH
cohort was by far the largest of the three, not
only in terms of the number of workers
exposed but also in terms of the number of
cancers observed during follow-up.
Recently, an additional 6 years of 
follow-up was conducted for the NIOSH
cohort (Steenland et al. 1999), and, more
important, a new exposure assessment was
developed that allowed an estimation of
TCDD exposure for all members of the
cohort (Steenland et al. 2001). This informa-
tion was not available in time to be incorpo-
rated into the U.S. EPA (2000) assessment.
We incorporated this new information from
the NIOSH cohort, along with the informa-
tion previously available for the Hamburg
and BASF cohorts, into a risk assessment sim-
ilar to that conducted by the U.S. EPA. We
compared results of this risk assessment to
those obtained by the U.S. EPA and by Starr
(2001). We also compared our results to risk
estimates based only on the NIOSH cohort
(Steenland et al. 2001) and only on the
Hamburg cohort (Becher et al. 1998). In
addition, we applied an analysis to determine
the lowest exposures for which there were sta-
tistically significant associations between
dioxin exposure and cancer mortality.
Review of New Data for 
NIOSH Cohort
The data for the NIOSH cohort used in the
U.S. EPA (2000) risk assessment were from
the Fingerhut et al. (1991) study, which
included follow-up through 1987. Steenland
et al. (1999) extended follow-up of this cohort
for an additional 6 years. They also developed
a cumulative exposure score for each member
of a subcohort of 3,538 workers (69% of total
cohort) obtained by eliminating workers with
inadequate exposure information or who were
exposed to pentachlorophenol in addition to
dioxin. This exposure score was based on work
history, the concentration of TCDD in
process materials, and a qualitative evaluation
of the potential for dermal and inhalation
exposure to TCDD-contaminated materials.
More recently, Steenland et al. (2001) derived
estimates of cumulative TCDD serum levels
for this subcohort based on a regression analy-
sis of exposure scores and serum lipid TCDD
concentrations available for 170 workers at one
of the NIOSH-studied facilities. This relation-
ship was then used to estimate the cumulative
serum lipid TCDD concentrations for all
3,538 workers based on the assumption that
TCDD uptake and elimination obeys first-
order pharmacokinetics. Steenland et al.
(2001) observed a significant positive trend
(p = 0.003) between all cancer mortality and
the logarithm of cumulative serum lipid
TCDD lagged 15 years.
Whereas Steenland et al. (2001) used
worker-speciﬁc data on both the plant and the
specific process, such information was not
available to the U.S. EPA (2000) or to Starr
(2001). Instead, the exposure analysis used by
the U.S. EPA and Starr assigned all workers in
broad categories of duration of exposure the
same cumulative serum level regardless of the
plant or job assignment within a plant or of
when exposure took place in relation to the
follow-up period. In the following sections we
incorporate the new Steenland et al. (1999,
2001) data for the NIOSH cohort into a meta-
analysis of the epidemiologic data for dioxin.
Meta-analysis methods. Our meta-analysis
is based on the same three occupationally
exposed cohorts as the U.S. EPA (2000) analy-
sis: the NIOSH cohort, the BASF cohort, and
the Hamburg cohort. Standardized mortality
ratio (SMR; the ratio of observed to expected
cancer deaths multiplied by 100) was the
response measure used in these studies.
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els that would result from lifetime intake of 7 pg TEQ/kg body weight/day, with no increase at 
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Research | ArticleMortality data for speciﬁc kinds of cancer were
not evaluated, and the term “cancer” refers to
mortality from all cancers. Cancer incidence
data were not available, and consequently risks
from nonfatal cancers were not reﬂected in the
data, and risks from rapidly fatal cancers car-
ried more weight than those from cancers with
better survival rates.
Exposure assessment. To make compar-
isons among different epidemiologic studies, it
is useful to have exposure quantiﬁed in a com-
mon metric that is plausibly related to risk.
Because our analysis was based on published
data, various aspects of the analysis, including
selection of the dose metric, were constrained
by the way in which data were presented in
the published reports. Cumulative serum lipid
concentration (CSLC; ppt-years) or area
under the serum lipid concentration curve was
selected as the exposure metric to relate to risk.
By comparison, the U.S. EPA used average
lifetime serum lipid concentration as the expo-
sure measure in its analysis (U.S. EPA 2000).
A time-dependent exposure such as CSLC
allows one to distinguish potential differences
in risks from different exposure patterns that
result in the same lifetime average exposure.
Flesch-Janys (1998) categorized observed
and expected cancer deaths in the Hamburg
cohort (n = 1,189) by quartiles of TEQ (unit
of measurement for TCDD-like compounds
that is deﬁned as the amount of TCDD that
would produce the same toxicity as a mixture
of TCDD-like compounds) CSLC (ppt-
years) reduced by the cumulative TEQ con-
tributed by background. Because only
exposure ranges were provided in Flesch-Janys
(1998), we specified average values within
these ranges—the midpoint for bounded
ranges and twice the lower bound for the
highest (unbounded) range. Observed and
expected numbers of cancer deaths, relative
risks, and the estimated exposures for the
Hamburg cohort are shown in Table 1.
Ott and Zober (1996) categorized cancer
deaths and SMRs in the BASF cohort 
(n = 247) by total intake of TCDD (micro-
grams per kilogram body weight) as a result of
the autoclave accident, estimated from
detailed work activity analysis and from
serum lipid TCDD concentrations measured
in a subset of workers. M. A. Zober (personal
communication) provided arithmetic average
total doses for each of the four exposure cate-
gories (0.015, 0.485, 1.38, and 3.72 µg/kg
body weight, respectively). To convert these
total intakes to TCDD CSLC, we divided
them by 0.25 (based on an assumed average
percent body fat of 25%) and by the decay
rate (0.099/year, corresponding to a half-life
of 7 years, as assumed by Ott and Zober).
The resulting data are shown in Table 1.
Steenland et al. (2001) computed risk
ratios categorized by septiles of TCDD CSLC,
including the contribution by background
exposures, using a 15-year lag (i.e., deﬁned so
that exposures in the most recent 15 years did
not contribute). These risk ratios used the low-
exposure group as the reference group and con-
sequently are not appropriate for our
meta-analysis, which needs the risks relative to
the normal background uncontaminated by
occupational dioxin exposure. Also, these risk
ratios depend on the observed risk in the low-
exposure group, which might involve consider-
able uncertainty. However, Steenland et al.
(1999) categorized observed cancer deaths and
expected deaths for the NIOSH cohort by sep-
tiles of the cumulative exposure score also
using a 15-year lag. As there was a high correla-
tion between the cumulative exposure score
and CSLC (Spearman correlation of 0.9;
Steenland et al. 2001), the CSLC for the
groups deﬁned by septiles of cumulative expo-
sure (Steenland et al. 2001) should be good
approximations of exposures in the comparable
groups deﬁned by the septiles of the exposure
index (Steenland et al. 1999). Consequently, in
our meta-analysis the CSLC (lagged 15 years,
TCDD half-life of 8.7 years assumed) from
Steenland et al. (2001) were applied to the can-
cer mortality data in Steenland et al. (1999).
Central values for the exposure ranges (anti-
logs of medians of log-transformed values)
were provided by K. Steenland (personal com-
munication). The resulting dose–response data
are shown in Table 1.
Dose–response modeling. The dose–
response data in Table 1 were modeled
assuming that the SMR depends linearly on
cumulative serum lipid concentration (CSLC,
in units of parts per trillion-year),
SMR = 100 ×α×(1 + β×CSLC), [1]
where 100 ×αis the baseline SMR and β is a
parameter that gauges the carcinogenic
potency of dioxin. This model was fit both
with the baseline SMR fixed at 100 (α ≡ 1)
and with variable baseline SMR (α estimated).
The ﬁtting was accomplished using maximum
likelihood, assuming that the observed cancers
in each exposure group were realizations of
independent Poisson variables, each with a
mean equal to the expected number of cancer
deaths derived from the comparison popula-
tion used by the original authors times the
SMR predicted by Equation 1 divided by 100.
The meta-analysis of the combined data from
the three studies was accomplished via the
combined likelihood of the three data sets in
Table 1. We used likelihood ratio tests to test
hypotheses, and we calculated confidence
intervals using the proﬁle likelihood method
(Crump 1995; Kodell and West 1993;
Venzon and Moolgavkar 1988). All hypothesis 
tests of individual parameters are two sided.
We used two types of analyses to evaluate
the cancer dose response. First, a series of
trend tests were applied to the data to deter-
mine the lowest dose for which there was a
statistically significant trend in SMR using
data from this dose and all lower doses, and
the highest dose for which there was no statis-
tically significant trend using data from this
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Table 1. Dose–response data from three epidemio-
logic studies.
Cumulative lipid, Cancer deaths
TCDD or TEQ (ppt-year) Obs Exp SMR
Flesch-Janys (1998)
180 25  23.3  107
988 34  20.8  164
3,416 31  23.3  133
10,425 34  20.8  164
Ott and Zober (1996)
605 8  10.0  80
19,614 8  6.7  120
55,645 8  5.7  140
150,454 7  3.5  200
Steenland et al. (1999, 2001)
260 67  68.4  98
402 27  30.0  90
853 31  27.2  114
1,895 30  25.4  118
4,420 34  25.6  133
12,125 33  19.5  169
59,838 34  22.1  154
Abbreviations: Exp, expected number of deaths; Obs,
observed number of deaths.
Table 2. Results of ﬁtting model 1 to data in Table 1.
95% CI
Baseline SMR = 100 (α = 1)
β (ppt-years)–1 (× 106)1 1 5.1–19
p-Value for test of β = 0 (no dioxin effect) 0.00007
Goodness-of-ﬁt p-value 0.05
ED10 (pg/kg/day) 266 161–587
ED05 129 78–285
ED01 25 15–56
Baseline SMR variable
α 1.17 1.04–1.30
p-Value for test of α = 1 0.008
β (ppt-years)–1 (× 106) 6.3 0.88–13
p-Value for test of β = 0 (no dioxin effect) 0.02
Goodness-of-ﬁt p-value 0.29
ED10 (pg/kg/day) 475 223–3,401
ED05 231 109–1,653
ED01 45 21–324dose and all lower doses (Tukey et al. 1985).
Second, we made estimates of ED10, ED05,
and ED01, the lifetime average daily TEQ
intakes (picograms per kilogram per day) cor-
responding to an increase of 0.1, 0.05, and
0.01, respectively, in the lifetime probability
of mortality from cancer.
To develop the trend analyses, we ordered
the data in Table 1 with respect to CSLC and
applied a likelihood ratio test for a signiﬁcant
exposure-related trend (i.e., test for β in
Equation 1 being signiﬁcantly different from
zero with α estimated) to the data. Then the
data at the highest exposure were omitted, and
the trend test was reapplied to the remaining
data. This procedure was applied repeatedly
until only the data for the lowest dose group
remained.
To estimate ED10, ED05, and ED01, we
computed the cumulative lipid concentration,
lagged 15 years, from a constant daily intake
as a function of age, assuming a)a   ﬁrst-order
elimination process with a 7.6 year half-life, 
b) a 50% systemic uptake of ingested dioxin,
c) that dioxin concentration in serum lipid is
an appropriate surrogate for dioxin concentra-
tion in total lipid, and d) that all dioxin is
sequestered in lipid, which comprises 25% of
body weight (U.S. EPA 2000). For a posited
long-term average daily intake, the resulting
cumulative age-specific lipid concentrations
were applied in conjunction with model 1 to
predict the age-speciﬁc mortality rates in the
presence of dioxin exposure. These were then
applied in a life-table analysis to predict the
lifetime risk of cancer in the presence of
dioxin exposure (Crump 1994). We calcu-
lated the additional risk posed by dioxin
exposure by subtracting from this lifetime risk
the corresponding risk assuming no addi-
tional exposure to dioxin above background.
To calculate an ED01, we adjusted the long-
term average daily intake to make the addi-
tional lifetime risk equal to 0.01. This
calculation used as baseline mortality rates for
all-cause mortality and all-cancer mortality
U.S. rates (both sexes and all races combined)
for 1985–1990.
Whereas background exposures are not
included in the exposures estimated for the
Hamburg and BASF cohorts (Table 1), the
NIOSH exposures include the contribution
of an assumed background of 5 ppt TCDD
in serum lipid. In the trend analyses, a back-
ground contribution of 3,000 ppt-years [e.g.,
50 ppt for 60 years, as U.S. EPA (2000)
reported that background TEQ lipid levels in
North America were about 55 ppt in the late
1980s] was added to the Hamburg and BASF
exposures in Table 1, and 2,700 ppt-years 
(45 ppt for 60 years, considering the 5 ppt
already included in the NIOSH estimates)
was added to the NIOSH exposures. Because
the background mortality rates used to calcu-
late ED01 already included any contribution
to cancer mortality from background dioxin
exposure, this adjustment for background
was not made in the ED01 calculations.
Consequently, the ED01 determined from our
analysis are best interpreted as long-term aver-
age daily intakes of TCDD or TEQ above the
current TEQ background that are predicted
to increase the lifetime probability of cancer
mortality by 0.01 above the current baseline
probability. The latter was estimated as 0.125
in our analysis and includes any contribution
by background levels of dioxin.
Results
Table 2 summarizes results of ﬁtting model 1
to the data in Table 1. The hypothesis of no
dioxin effect (β = 0) was rejected (p = 0.00007)
when the baseline SMR was ﬁxed at 100 and
also when the baseline SMR was estimated 
(p = 0.02). Because the hypothesis that the
baseline SMR = 100 (α =1) was rejected 
(p = 0.008), the results in Table 2 obtained
with baseline SMR variable (α estimated, bot-
tom half of Table 2) are preferred. The linear
model provided an adequate fit to the data
(goodness-of-ﬁt p = 0.29), produced a baseline
SMR estimate of 100α = 117 [95% conﬁdence
interval (CI), 104–130], and predicted that
each part per trillion-year of cumulative lipid
concentration increased the relative risk by β =
6.3 × 10–6 (95% CI, 8.8 × 10–7–1.3 × 10–5).
To test for potential nonlinearity in the
dose response, model 1 was expanded by
replacing CSLC with CSLCK, K ≥ 1. This
expanded model is linear if K = 1 and is sublin-
ear (threshold-like) if K > 1. The best estimate
of K was 1, indicating there was no evidence of
sublinearity in the dose response. Although
models with K < 1 (supralinear models) pro-
vided even better ﬁts (and higher risks), these
were discounted because they produce an inﬁ-
nite slope to the exposure–response curve at
zero exposure, which is not considered 
biologically plausible.
Figure 1 shows the SMRs from the three
studies and corresponding 95% CIs, plotted
against CSLC (log scale) in Table 1 after
adjusting as described earlier to include back-
ground TEQ CSLC. The fit of the linear
model 1 with variable baseline SMR is also
displayed. This ﬁgure provides a visual conﬁr-
mation of the adequacy of the linear model to
describe these data.
Figure 1 suggests possible nonhomogene-
ity in the dose responses of the three studies
because all four data points from Ott and
Zober (1996) are below the predicted curve,
and three of four data points from Flesch-
Janys et al. (1998) are above the predicted
curve. A likelihood ratio test of whether sepa-
rate β for each study provided a better fit to
the data was nonsigniﬁcant (p = 0.13, 2 df). A
test of whether both separate β and separate α
provided a better fit was also nonsignificant 
(p = 0.17, 4 df). These results suggest that
perhaps some, but not extreme, heterogeneity
exists among studies and consequently sup-
ports a combined analysis of data from all
three studies using a common model.
Table 2 provides ED01, ED05, and ED10,
calculated with both the baseline SMR ﬁxed
at 100 and with the baseline SMR variable.
As noted above, results from the latter model
are preferred because the hypothesis that the
baseline SMR = 100 was rejected (p = 0.008)
and the model with the baseline variable pro-
vided a good fit to the data (p = 0.29). The
model with variable baseline predicted ED10
= 475 pg/kg/day (95% CI, 223–3,401), ED05
= 231 pg/kg/day (95% CI, 109–1,653) and
ED01 = 45 pg/kg/day (95% CI, 21–324).
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Figure 1. SMRs (with 95% conﬁdence bounds) from three studies categorized by cumulative lipid concen-
tration (Table 1), adjusted to include background TEQ.
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■ ■It was noted earlier that exposures were
lagged 15 years in the Steenland et al. (1999,
2001) study but not lagged in the remaining
studies. In our calculations of ED10, ED05,
and ED01 we used a 15-year lag. Some lag
seemed appropriate because exposures imme-
diately before death are not likely to inﬂuence
the cancer response. Because Steenland et al.
(1999, 2001) used a 15-year lag and the
majority of the data were from this study, we
decided to use a 15-year lag in the calcula-
tions. When no lag was used (results not
shown), the estimated ED10, ED05 and ED01
were smaller by roughly 40%.
Table 3 gives the results from the series of
trend tests. The trend was significant (p =
0.02) when all the data were included. When
the data at the highest exposure were omitted,
the trend remained signiﬁcant (p = 0.04) and
the slope, β, increased. As the nine highest-
dose groups were successively omitted, the
dose–response slope, β, increased at each step
until only doses of 3,988 ppt-years or lower
remained. Also, as successive data points were
omitted, the trend remained significant 
(p ≤ 0.05) through the step at which only the
data corresponding to a cumulative serum
level of 7,120 ppt-years or lower were left.
When the 7,120 ppt-years data point was
omitted leaving 6,416 ppt-years as the highest
dose, the trend became barely nonsigniﬁcant
(p = 0.07) and remained so as the next data
point was omitted. However, the trend again
became signiﬁcant (p = 0.04) when the highest
exposure remaining was 3988 ppt-years.
Statistical signiﬁcance was not obtained when
the 3,988 ppt-years group was omitted (leav-
ing 3,853 ppt-years as the highest remaining
exposure) or when subsequent dose groups
were omitted. Thus, there is consistent statisti-
cal evidence of an exposure effect at 7,120
ppt-years and above. There is, however, also
statistical support for an effect at 3,988
ppt-years and above.
Discussion 
U.S. EPA analysis. The dose–response assess-
ment methodology applied to epidemiology
data in the U.S. EPA (2002) draft health
effects dioxin document differed from our
analysis in three main ways. First, rather than
using the Steenland et al. (1999, 2001) study,
the U.S. EPA used the Fingerhut et al. (1991)
study, which included 6 fewer years of follow-
up and a less detailed exposure assessment.
Second, the U.S. EPA used average body bur-
den as the exposure metric, whereas we used
cumulative serum lipid concentration. Third,
the U.S. EPA assumed a baseline SMR of 100,
whereas we allowed the baseline SMR to
increase above 100 because the hypothesis that
SMR = 100 could be rejected. The U.S. EPA
did not conduct a formal test of the hypothesis
that SMR =100 nor did they report on the ﬁt
of the model to the data. However, Starr
(2001) reproduced the U.S. EPA analysis and
concluded that the model did not fit ade-
quately. Based on their meta-analysis, the U.S.
EPA estimated an ED01 = 47 ng/kg body bur-
den (95% lower bound: 30 ng/kg). This body
burden is estimated (Table 4) to correspond to
a daily intake of 23 pg/kg/day (95% lower
bound: 15 pg/kg/day).
Starr analysis. Starr (2001) conducted a
critique of the U.S. EPA (2000) risk assess-
ment for dioxin that included a meta-analytic
evaluation of the same dose–response data
from the NIOSH, Hamburg, and BASF stud-
ies as was used by the U.S. EPA in its meta-
analysis. Starr concluded that the data from
these three studies were consistent (goodness-
of-fit p-value = 0.31) with an elevated back-
ground (SMR = 132) and no exposure effect.
In contrast, our comparable analysis, based
upon the updated NIOSH data, found a sig-
niﬁcant dose–response trend (p = 0.01).
Applying the same linear model for 
relative risk as the U.S. EPA (constraining the
background SMR = 100), Starr (2001) esti-
mated an ED01 body burden concentration of
47 ppt (95% lower bound: 28 ppt), which
agrees with the U.S. EPA results. However,
Starr noted that this model did not describe
the data adequately (goodness-of-ﬁt p-value =
0.0003). When the background SMR was esti-
mated, the linear model provided an adequate
fit (goodness-of-fit p-value = 0.31) and an
ED01 = 145 ppt (95% lower bound: 49 ppt).
This body burden is estimated (Table 4) to
correspond to a daily intake of 72 pg/kg/day
(95% lower bound: 24 pg/kg/day). However,
the ﬁt of the intercept-only model was equally
as good as that of the linear model.
Steenland et al. analysis. Steenland et al.
(2001) conducted a quantitative risk assess-
ment using only the updated data from the
NIOSH study. A signiﬁcant (p = 0.003) posi-
tive dose–response trend was found between
estimated log cumulative TCDD serum level
and all-cancer mortality. Steenland et al. esti-
mated additional lifetime risk of cancer from
TCDD exposure using two models. One
model assumed that relative risk was a linear
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Table 3. Tests results for dose–response trend applied to data ranked by CSLC, adjusted to include back-
ground TEQ.
CSLC Cancer deaths β (Slope)a Trend
(ppt-year) Obs Exp SMR Study (ppt-year)–1 p-valuea
153,434 7 3.5 200 Ott and Zober (1996) 5.7 × 10–6 0.02**
62,538 34 22.1 154 Steenland et al. (1999, 2001) 7.6 × 10–6 0.04**
58,645 8 5.7 140 Ott and Zober (1996) 1.6 × 10–5 0.05**
22,614 8 6.7 120 Ott and Zober (1996) 4.6 × 10–5 0.005***
14,825 33 19.5 169 Steenland et al. (1999, 2001) 6.7 × 10–5 0.001***
13,435 34 20.8 164 Flesch-Janys (1998) 7.8 × 10–5 0.008***
7,120 34 25.6 133 Steenland et al. (1999, 2001) 1.2 × 10–4 0.05**
6,416 31 23.3 133 Flesch-Janys (1998) 1.9 × 10–4 0.07*
4,595 30 25.4 118 Steenland et al. (1999, 2001) 6.4 × 10–4 0.08*
3,988 34 20.8 164 Flesch-Janys (1998) 1.7 × 10–1 0.04**
3,605 8 10.0 80 Ott and Zober (1996) 4.8 × 10–5 0.78
3,553 31 27.2 114 Steenland et al. (1999, 2001) 4.0 × 10–4 0.49
3,180 25 23.3 107 Flesch-Janys (1998) 0 1
3,102 27 30.0 90 Steenland et al. (1999, 2001) 0 1
2,960 67 68.4 98 Steenland et al. (1999, 2001)
aSlope and two-sided p-value for dose–response trend obtained using data from given exposure group and all groups
with lower CSLC. *p = 0.1; **p = 0.05; ***p = 0.01.
Table 4. Summary of ED01 estimated from linear or piecewise linear dose–response models.a
pg/kg/day intake Steady-state body burden, ppt Goodness-of-ﬁt
Study and model Background SMR ED01 95% LB 95% UB ED01 95% LB 95% UB p-value
Becher et al. (1998), linear Effectively estimated  4.5 NR NR 9.1 NR NR NR
U.S. EPA (2000), linear Fixed (=100) 23 15 NR 47 30 NR NR
Starr (2001), linear Fixed (=100) 24 14 NR 47 28 NR 0.003
Estimated 72 24 Inﬁnite 145 49 Inﬁnite 0.31
Steenland et al. (2001), piecewise linear Effectively estimated 7.7 5.0b 19b 15b 10b 37 b NR
Present study, linear Fixed (=100) 25 16 47 51 33 95 0.08
Estimated 45 23 173 91 47 346 0.29
Abbreviations: LB, lower bound; NR, not reported; UB, upper bound.
aThe relationship between daily intake and steady-state body burden was determined assuming ﬁrst-order pharmacokinetics, half-life of 7.6 years, 50% systemic uptake of TCDD, TCDD
sequestered only, and homogeneously, in lipid, which forms 25% of human body by weight. b97.5% bounds rather than 95%.function of log TCDD CSLC lagged 15 years,
and the second assumed that relative risk was a
piecewise linear function of (untransformed)
TCDD CSLC with no lag.
The piecewise linear model selected by
Steenland et al. had a change in slope at a
cumulative serum level of 40,000 ppt-years;
this break-point was determined by a process
of elimination. A threshold model was found
not to signiﬁcantly improve the ﬁt. The use of
the piecewise model caused the risk estimates
to be larger than what would be obtained
using a purely linear model.
Based on the piecewise linear model,
Steenland et al. estimated an increased lifetime
risk of 0.0005 in males and 0.0004 in females
from an incremental exposure of 1 pg/kg/day
TCDD over the risk at a background exposure
to 0.5 pg/kg/day. Using the same model, they
estimated an increased lifetime risk of 0.0071
in males and 0.0060 in females from an incre-
mental exposure of 10 pg/kg/day TEQ over
the risk at a background exposure to 
5 pg/kg/day. Because the background TEQ
exposure of 5 pg/kg/day is the more realistic
scenario, we focus on the average risk in males
and females under this scenario. Because the
model is linear in this exposure range, an addi-
tional lifetime risk of 0.0065 from an addi-
tional exposure to 5 pg/kg/day is equivalent to
an ED01 = 5 × (0.01/0.0065) = 7.7 pg/kg/day
(95% CI, 5.0–19).
The log-linear model used by Steenland 
et al. predicted risks of up to 20-fold higher
than those predicted by the piecewise linear
model. However, Steenland et al. noted that
this model may be unrealistic and expressed a
preference for the piecewise linear model.
Results from the log-linear model are not
considered further here.
Becher et al. analysis. Becher et al. (1998)
conducted a quantitative dose–response
assessment using only the data from the
Hamburg study. Cumulative lipid concentra-
tion over time, with a lag of either 0 of 10
years, was used as the exposure variable. A
number of Poisson and Cox regressions were
used to investigate dose–response relations,
and in each analysis TCDD and TEQ expo-
sures were signiﬁcantly related to total cancer.
To evaluate the shape of the dose response,
Becher et al. considered three mathematical
forms for relative risk: the multiplicative
model: relative risk (RR) = eβd, where d is
cumulative TCDD or TEQ exposure; the
additive model: RR = 1 + βd (equivalent to
our linear model, Equation 1); and the power
model: RR = (1 + βd)k, which is an extension
of the additive model. In the basis of each of
these models, a linear relationship between
exposure and lifetime risk was assumed by
Becher et al. in the low-dose range. Similar
risks were estimated for males and females
separately and combined, and for no exposure
lag and for a 10-year lag; consequently, only
results for males and females combined using
a 10-year lag are discussed here. Using these
models, Becher et al. estimated the additional
lifetime risk of mortality from total cancer
from lifetime daily intake of 1 pg/kg dioxin to
be 0.0012 (multiplicative model), 0.0022
(additive model) and 0.0052 (power model).
The additive model provided a slightly bet-
ter ﬁt (higher likelihood) than the multiplica-
tive model, and the power model predicted a
supralinear dose response that provided only a
very minor, statistically insigniﬁcant improve-
ment over the fit provided by the additive
model. The lifetime risk of 0.0022 from intake
of 1 pg/kg dioxin per day (additive model) is
equivalent to an ED01 = 0.01/0.0022 = 4.5
pg/kg/day. Although this analysis was based on
TCDD serum levels, the slope Becher et al.
obtained (β = 0.018 ppt–1) was similar to the
slope they obtained using TEQ serum levels
(β = 0.0175 ppt–1). Consequently, it appears
that a similar ED01 would have been obtained
using TEQ serum levels.
Present analysis. The new NIOSH data
(Steenland et al. 1999, 2001), which incorpo-
rates 6 additional years of follow-up and a
detailed exposure analysis, provides new
information on the potential carcinogenicity
of dioxin. Based on a meta-analysis of data
from three epidemiological cohorts, including
the old NIOSH data, Starr (2001) did not
find a statistically significant relationship
between dioxin exposure and total cancer.
However, using the data from the same three
cohorts but incorporating the new NIOSH
data, we did ﬁnd a statistically signiﬁcant rela-
tionship between dioxin exposure and cancer
(p = 0.02).
Because we lacked the necessary data, we
were not able to evaluate the likelihood that
confounding with lifestyle factors or occupa-
tional exposures to other chemicals may have
been responsible for the observed responses in
the individual studies. However, fitting 
model 1 with the background SMR as an esti-
mated parameter effectively compared the
responses of workers exposed to different
amounts of dioxin. Thus, confounding as an
explanation for the association is less of a con-
cern for the comparison in the present analy-
sis than it would be if direct comparisons
were made of exposed workers to an external
comparison group. Similarly, Steenland et al.,
using internal comparisons based on Cox
regression, found signiﬁcant trends in cancer
in the NIOSH data with logarithm of cumu-
lative exposure score, cumulative exposure
score after omitting the highest 1% of expo-
sure scores (Steenland et al. 1999), and loga-
rithm of cumulative serum level (Steenland 
et al. 2001).
The trend analysis (Table 3) demonstrates
statistical evidence of an association between
dioxin TEQ exposure and cancer mortality
for TEQ CSLCs of 3,988 ppt-years and
higher. The highest dose where a trend was
not supported by the analysis is a TEQ CSLC
of 3,605 ppt-years. In addition, this analysis
does not support the frequently quoted obser-
vation that the human evidence for dioxin
carcinogenicity is limited to populations with
very high exposures. If anything, our analysis
suggests the contrary because the slope of the
dose–response curve increased as higher doses
were successively omitted (Table 3). The lack
of statistical significance at the lowest doses
does not necessarily indicate the absence of a
dioxin effect in this dose range because this
could be the result of a reduction in statistical
power as higher doses are omitted.
The estimated long-term average daily
intake corresponding to a cumulative lifetime
(to age 70) exposure of 3,988 ppt-years is 
7 pg/kg/day. By comparison, based on com-
bined analysis of fat intake, estimates of average
dioxin intake, and variation in serum dioxin
levels, current average human daily intake is
estimated to be about 1 pg/kg/day TEQ, with a
99% percentile of 3 pg/kg/day (U.S. EPA
2000). Thus, while current U.S. foodborne
exposures are not likely to range up to the levels
where our analysis found significant associa-
tions with cancer mortality, our analysis pro-
vides some evidence that TEQ exposures near
current background levels are carcinogenic.
The linear dose–response model based on
cumulative exposure described the data well
(goodness-of-fit p-value = 0.29), despite the
fact that the cohort members experienced pat-
terns of exposure ranging from acute (e.g.,
from the autoclave accident in the BASF
plant) to longer-term exposures. Moreover,
there was no statistical evidence of a sublinear
dose response or threshold. Our trend analysis
(Table 3) taken at face value indicates that if a
threshold for the carcinogenicity of dioxin
exists, it is likely below a cumulative serum
level of 4,000 ppt-years.
Despite the statistical significance of the
test for dose–response trend in our meta-
analysis (p = 0.02), the data were marginally
consistent, according to a goodness-of-ﬁt test,
with no effect of exposure and a background
SMR of 124 (goodness-of-ﬁt p-value = 0.08).
However, a goodness-of-fit test does not
speciﬁcally evaluate the hypothesis of increas-
ing response with increasing exposure to
dioxin. In contrast, a trend test provides a
speciﬁc and statistically more powerful evalu-
ation of this hypothesis.
There are several differences in the expo-
sure estimates for the three epidemiological
studies used in our meta-analysis. First, the
NIOSH estimates used a 15-year lag, whereas
no lag was used with the other cohorts. Given
that follow-up in the Steenland et al. (2001)
cohort extended for many years past the time
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results based on cumulative exposure lagged
15 years should not differ greatly from those
based on unlagged exposure.
A second difference in the exposure esti-
mates is that those for the Hamburg cohort
included total TEQ (Flesch-Janys et al. 1998),
whereas estimates for the NIOSH (Steenland
et al. 1999, 2001) and BASF (Ott and Zober
1996) cohorts quantiﬁed only TCDD. Based
on the available lipid samples from workers,
total TEQ exposures in the Hamburg cohort
appear to have been primarily a result of
exposure to TCDD (Ott et al. 1993; Ott and
Zober 1996; Piacitelli et al. 1992), whereas
total lipid TEQ in the Hamburg cohort were
estimated to be about twice that resulting
from TCDD alone (Flesch-Janys et al. 1998).
Steenland et al. omitted (and, consequently,
so does this analysis) all workers in the
NIOSH cohort who were exposed to pen-
tachlorophenol, which is contaminated with
dioxins other than TCDD. Thus, it appears
that the exposure estimates available for each
cohort are reasonable estimates of total TEQ
exposures.
A third difference in the exposure esti-
mates is that the exposures for the NIOSH
cohort included 2,3,7,8-TCDD background
exposures, whereas the exposures for the
Hamburg and BASF cohorts did not include
any background. In the trend analysis (Table 3, 
Figure 1), the exposures in Table 1 were
modiﬁed (2,700 ppt-years added to NIOSH
exposures and 3,000 ppt-years to Hamburg
and BASF exposures) to include TEQ contri-
butions to background. However, we
obtained similar results (not shown) in the
trend analysis when no background adjust-
ment was made and also when 300 ppt-years
was subtracted from NIOSH exposures. No
adjustment for background was made in the
calculations of ED01, and these are best inter-
preted as pertaining to additional risk over
any that may exist from background expo-
sures. However, these estimates are based on a
linear model and consequently will be insensi-
tive to how background exposures are han-
dled as long as the CSLC background is small
relative to 1/β, which is the case here. As a
veriﬁcation of this, the analysis leading to our
ED01 of 45 pg/kg/day (Tables 2, 4) was
repeated using the exposures adjusted for
background (Table 3, Figure 1); the resulting
change in the ED01 was less than 3%.
There is some evidence that at high expo-
sures liver enzymes are induced that increase
the elimination rate of dioxin compounds
(Carrier et al. 1995). Such an effect was not
accounted for in the analyses discussed here,
but rather in each case ﬁrst-order pharmaco-
kinetics was assumed. Based on the estimated
maximum body burdens in these studies, the
amount of underestimation of the cumulative
exposures from not accounting for enzyme
induction is expected to be at most a factor of
1.5 for the upper dose levels (Van der Molen
et al. 2000; Zeilmaker et al. 1998).
Table 4 summarizes ED01 estimates
derived from linear (or piecewise linear) mod-
els. The U.S. EPA (2000) ED01 estimate and
the estimate by Starr (2001) with baseline
SMR = 100 agree closely (23–24 pg/kg/day),
as expected since Starr’s calculation is
intended as a reproduction of that of the
U.S. EPA. However, Starr showed that this
model provided an inadequate ﬁt to the data
(p < 0.003). It is interesting that our meta-
analysis with SMR = 100 also predicted a
similar ED01 (25 pg/kg/day), as there are a
number of differences between our calcula-
tions and those of the U.S. EPA and Starr.
We used the updated follow-up and exposure
data for the NIOSH cohort and used cumu-
lative lipid serum concentration as the expo-
sure measure, whereas the U.S. EPA and
Starr used the earlier NIOSH data and used
average body burden as the exposure metric.
Because the hypothesis that background
SMR = 100 was rejected (p = 0.008), the
model with background SMR estimated is the
preferred one from our meta-analysis. This
model predicted an ED01 = 45 pg/kg/day and
was based on a statistically significant linear
trend (p = 0.02). This estimate is also pre-
ferred over Starr’s estimate of 72 pg/kg/day
because it reﬂects the updated follow-up and
more precise exposure estimates for the
NIOSH cohort.
The estimate of ED01 = 4.5 pg/kg/day
from the linear model applied by Becher 
et al. (1998) to the Hamburg data is 10-fold
smaller than our preferred estimate of 
ED01 = 45 pg/kg/day based on data from all
three cohorts. This difference is mainly attrib-
utable to differences in the underlying data.
When we restricted our analysis to just
the Hamburg data, we obtained an ED01 =
11 pg/kg/day, and when we repeated this
analysis using Hamburg TCDD exposures
rather than TEQ exposures, we obtained an
ED01 = 4 pg/kg/day.
Our preferred ED01 of 45 pg/kg/day is 
6 times higher than the Steenland et al. (2001)
estimate of 7.7 pg/kg/day. We have not deter-
mined the full basis for this difference,
although contributing factors are known. Both
analyses estimate cancer risk above that of an
unexposed worker population rather than of an
external comparison population. Effects of dif-
ferent assumptions regarding pharmacokinetic
parameters (uptake fraction, half-life, and per-
cent lipid) and background exposures appear
minor. Part of the difference is attributable to
the fact that the Steenland et al. analysis was
based only on the NIOSH cohort, and our
analysis also incorporated the data from the
BASF and Hamburg cohorts. However,
when we repeated our analysis using only
the NIOSH data, our ED01 estimate only
decreased from 45 pg/kg/day to 32 pg/kg/day.
The most likely reason for the remaining dif-
ference is that, whereas we used a purely linear
model, Steenland et al. used a piecewise linear
model with a break in the slope at a CSLC of
40,000 ppt. Use of the piecewise linear model
resulted in a smaller ED01 than would have
been obtained using a linear model. However,
it should be kept in mind that none of these
models can be veriﬁed at low exposure levels.
At present we do not see a clear choice
between our ED01 estimate of 45 pg/kg/day
and the Steenland et al. (2001) estimate of
7.7 pg/kg/day. Our estimate has the advan-
tage of drawing from three different studies.
On the other hand, the Steenland et al. esti-
mate has the advantage of being based on
individual worker data from the largest of the
three studies rather than summarized data. If
the different policy implications of the two
estimates are large, it could be worthwhile to
conduct an analysis that combines the best
features of each and perhaps includes data
from other cohorts with extensive TCDD
exposure evaluation, such as the Dutch acci-
dent cohort (Hooiveld et al. 1998).
Overall, the available dose–response
assessments for dioxin and cancer indicate
that dioxin TEQ exposures within roughly 
3-fold of current background levels may be
carcinogenic. The proximity of foodborne
dioxin exposure levels to those associated with
cancer argues for careful consideration of both
the cancer mechanism and the upper ranges
of long-term average exposures for dioxins.
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